Novo Nordisk A/S
NONOF
Rank in Stocks
#111
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$41.21
Last synced: 2026-11-09
Market Cap
$180.56B
Change (1 day)
2.94%
Change (1 year)
-16.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Novo Nordisk A/S (NONOF)
Category
Healthcare
EPS for Novo Nordisk A/S (NONOF)
EPS as of September 2026 TTM: $3.79
According to Novo Nordisk A/S's latest financial reports, its current EPS (TTM) is $3.79. At the end of 2025 the company had an EPS of $3.61, an increase over its 2024 EPS of $3.16.
EPS history for Novo Nordisk A/S from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $3.79 | 4.94% |
| 2025 | $3.61 | 14.17% |
| 2024 | $3.16 | 128.82% |
| 2023 | $1.38 | -21.63% |
| 2022 | $1.76 | 10.95% |
| 2021 | $1.59 | 7.35% |
| 2020 | $1.48 | 140.78% |
| 2019 | $0.62 | 0.41% |
| 2018 | $0.61 | -50.68% |
| 2017 | $1.24 | 16.81% |
| 2016 | $1.06 | 7.67% |
| 2015 | $0.99 | 20.28% |
| 2014 | $0.82 | -5.24% |
| 2013 | $0.87 | -37.33% |
| 2012 | $1.38 | 162.51% |
| 2011 | $0.53 | 18.44% |
| 2010 | $0.44 | 28.33% |
| 2009 | $0.35 | 18.46% |
| 2008 | $0.29 | 9.83% |
| 2007 | $0.27 | 50.17% |
| 2006 | $0.18 | 25.90% |
| 2005 | $0.14 | 3.45% |
| 2004 | $0.14 | 12.38% |
| 2003 | $0.12 | 45.50% |
| 2002 | $0.08 | 24.70% |
| 2001 | $0.07 | 20.36% |
| 2000 | $0.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $30.89 | 715.41% |
US
|
|
| $6.60 | 74.22% |
US
|
|
| $5.83 | 53.89% |
US
|
|
| $0.98 | -74.13% |
US
|
|
| $18.54 | 389.45% |
CH
|
Questions about Novo Nordisk A/S's earnings per share (EPS)
What is Novo Nordisk A/S's earnings per share (EPS)?
Novo Nordisk A/S's earnings per share (EPS) over the last twelve months is $3.79, as of Sep 2026.
What was Novo Nordisk A/S's earnings per share (EPS) in 2025?
In 2025, Novo Nordisk A/S's earnings per share (EPS) was $3.61, 14.24% more than in 2024 ($3.16).
How has Novo Nordisk A/S's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Novo Nordisk A/S's earnings per share (EPS) went from $1.48 to $3.61, an average growth of 19.52% a year.
How does Novo Nordisk A/S's earnings per share (EPS) compare with similar companies?
Novo Nordisk A/S's earnings per share (EPS) ($3.79) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Eli Lilly and Company, with $30.89.